Moleculin Biotech
MBRX
15 hedge funds and large institutions have $348K invested in Moleculin Biotech in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
124% more capital inflows, than outflows
Capital inflows: $432K | Capital outflows: $192K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
1.07% more ownership
Funds ownership: 1.78% → 2.85% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$248K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.8K |
| 3 |
HRT Financial
New York
|
+$45.5K |
| 4 |
Rockefeller Capital Management
New York
|
+$13.9K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$1.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$110K |
| 2 |
Jane Street
New York
|
-$74.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.14K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$119 |
MBRX Hedge Fund Activity: Q1 2026 in Review
15 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2026, worth a combined $348K — up 10% from $315K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MBRX positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $248K. The largest seller was Citadel Advisors, exiting entirely with an estimated $110K sold.
- 15 institutional investors held Moleculin Biotech (MBRX) as of Q1 2026, up from 14 in Q4 2025.
- Funds reported $348K of Moleculin Biotech stock for Q1 2026, up 10% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q1 2026 and 3 closed out, a net change of +2 holders.
- The largest Moleculin Biotech buyer in Q1 2026 was Sabby Management, an estimated $248K added.
- The largest Moleculin Biotech seller in Q1 2026 was Citadel Advisors, an estimated $110K sold.
Based on aggregated 13F filings for Q1 2026.